Abstract Parathyroid hormone and parathyroid hormonerelated protein lower blood pressure and relax contracted arteries. Parathyroid hormone also attenuates angiotensin H-induced vasoconstriction. To determine the cellular mechanism or mechanisms by which parathyroid hormone analogues antagonize pressor effects, we examined the effect of these peptides on angiotensin II-induced calcium mobilization in fura 2-AMloaded cultured rat vascular smooth muscle cells. Either 100 nmol/L parathyroid hormone or parathyroid hormone-related protein significantly reduced the amount of calcium mobilized by 100 nmol/L angiotensin II. The attenuating effect of these peptides was mimicked by 10 mmol/L forskolin and 10 mmol/L isobutylmethylxanthine and was not dependent on the presence of extracellular calcium. This effect of the parathyroid hormone analogues was reduced when cells were pretreated with 100 mmol/L 2',5'-dideoxyadenosine, an adenylate cyclase inhibitor. Combined inhibition of cyclic nucleotide-dependent protein N umerous studies have consistently demonstrated that parathyroid hormone (PTH), as either intact hormone or the N-terminal 1-34 fragment of PTH [PTH(l-34)], relaxes contracted vessels and lowers blood pressure in a variety of animal species.
cular smooth muscle, the mechanism or mechanisms by which these peptide hormones cause these effects on blood vessels have not been completely elucidated. PTH can induce relaxation by blocking L-type channels in vascular smooth muscle cells (VSMCs) . 12 This effect is probably mediated through an adenylate cyclase-dependent mechanism. PTH(l-34) increases adenylate cyclase activity in kidney cells, 13 bone cells, 14 and vascular tissue, 15 as does PTHrp(l-34). 16 Adenylate cyclase stimulation results in production of cyclic AMP (cAMP), which has been shown to inhibit elevations of intracellular calcium ([Ca 2+ ],) in VSMCs. This [Ca 2+ ],-lowering effect is probably mediated through the stimulation of cAMP-or cyclic GMP (cGMP)-dependent protein kinases. 17 ' 18 Increased VSMC [Ca 2+ ], is believed to be an initial step in intracellular signaling for vascular contraction. It has also been shown that PTH antagonizes arginine vasopressin-induced 43 Ca 2+ uptake and contraction in VSMCs via an adenylate cyclase-dependent mechanism. 19 However, in addition to Ca 2+ influx being a source of this [Ca 2+ ]i signal, many vasoconstrictors, such as Ang II, also mobilize Ca 2+ from intracellular stores such as the sarcoplasmic reticulum. Any factor that decreases intracellular release of vascular smooth muscle Ca 2+ may also induce vasodilation as a result of this decrease.
Based on this knowledge, we have examined the pathways for intracellular signaling produced by PTH(l-34) and to test the hypothesis that these peptides attenuate agonist-induced increases of calcium mobilized from intracellular stores in VSMCs through an adenylate cyclase-dependent mechanism.
Methods

Cell Cultures
Primary VSMCs were prepared by enzymatic dispersion of thoracic aorta segments obtained from male Sprague-Dawley rats (250 to 300 g, Bantin and Kingman) using methods previously employed in this laboratory. 20 All animal procedures were approved by the Seputveda Veterans Affairs Medical Center Animal Studies Subcommittee. The harvested cells were grown in Dulbecco's modified Eagle medium (DMEM, Sigma Chemical Co) supplemented with 10% fetal calf serum (Hyclone Laboratories), 50 U/mL penicillin, and 50 mg/mL streptomycin (Sigma). For these studies, cells were grown in six-well plates and seeded at a density that reached confluence in 2 to 4 days. VSMCs were authenticated by randomly screening cultures for smooth muscle actin expression using immunofluorescent staining techniques.
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Measurement of VSMC [Ca 2+ ],
Cells were seeded onto 25 -mm-diaraeter glass coverslips in six-well plates. After the cells reached confluence, the medium was replaced with serum-free medium for 16 to 20 hours. Then the medium was replaced with a HEPES-buffered physiological salt solution (HPSS) containing (mmol/L) HEPES 10, NaCl 145, KC1 5, MgSO 4 1, sodium phosphate 0.5, glucose 6, and CaCl 2 2 (pH 7.4 at 37°C). Cells were incubated with 4 mmol/L fura 2-AM for 40 minutes at 37°C and then incubated with fresh HPSS for 20 minutes at 37°C. The coverslips were rinsed with fresh HPSS and inserted into a thermoregulated stage incubator (37°C) filled with 1 mL HPSS and mounted on an epifluorescence microscope (model IMT-2, Olympus Optical Co). The microscope was integrated into a PTI Deltascan-1 spectrofluorometer (Photon Technology International) that rapidly alternated excitation wavelength between 340 and 380 nm and detected emission at 510 nm. A confluent field of cells was located using a x 40 oil immersion fluorescence lens, and the emissions ratio (340/380) resulting from the alternating excitation wavelengths was recorded every 0.5 seconds using an AT-compatible computer. Each coverslip was calibrated after experimentation by first treating the cells with 1 mmol/L ionomycin (Calbiochem) and 4 mmol/L EGTA in calcium-free HPSS to determine the minimal fluorescence ratio. The maximal fluorescence ratio was obtained by subsequently treating the cells with 10 mmol/L CaCl 2 and 1 mmol/L ionomycin. Autofluorescence of each field of cells was determined by quenching all fura 2 dye with 4 mmol/L MnCl 2 . After autofluorescence was subtracted from all recorded measurements, [Ca 2+ ]| was calculated using the equation of Grynkiewicz et al, 21 with a ^ of 224 for fura 2. ]i response (<100 nmol/L increase) to Ang II under control conditions were discarded. To test the dependence of the modulating effect of PTH(l-34) on extracellular calcium, we incubated some coverslips with calciumfree HPSS containing 5 mmol/L EGTA and repeated the above procedure.
Determinations of Effects of Parathyroid
To determine whether the attenuating effect of PTH(l-34) on Ang Il-induced calcium mobilization was dependent on a cAMP-or cGMP-dependent protein kinase or a protein kinase C (PKC) pathway, we preincubated VSMCs for 15 minutes with 50 mmol/L Af-[2-(methylamino)-ethyl]-5-isoquinolinesulfonamide, di-HCl (H-8, Calbiochem), which inhibits cAMP-and cGMP-dependent protein kinases, or with 1 mmol/L staurosporine (Calbiochem), which inhibits PKC. Then the effect of PTH(l-34) on the Ang Il-induced calcium mobilization was examined as described above.
To determine the effect of adenylate cyclase inhibition on the ability of PTH(l-34) to attenuate the Ang Il-induced calcium signal, we preincubated coverslips with VSMCs for 20 minutes with 100 mmol/L 2',5'-dideoxyadenosine (DDA, Pharmacia), an adenylate cyclase inhibitor, 22 before treatment with PTH(l-34) and subsequent stimulation with Ang II.
Measurement of cAMP
VSMC cAMP concentrations were measured after 5 minutes of stimulation with PTH(l-34) or PTHrp(l-34) as described by Nickols. 15 Confluent cultures of VSMCs in six-well plates were deprived of serum overnight. Culture medium was replaced with HPSS for 60 minutes, and then cells were washed and 1 mL HPSS was placed in each well. DDA or vehicle (100 mmol/L) was added to each well. After preincubation for 20 minutes, 100 nmol/L PTH(l-34), PTHrp(l-34), PTH(3-34), 10 mmol/L forskolin, or vehicle was added to the respective wells. After 5 minutes of incubation, HPSS was aspirated from all cultures, and cAMP was extracted from VSMCs with 0.1N HC1 for 10 minutes. These acidic extracts were evaporated and stored at -20°C until assayed for cAMP using a commercially available radioimmunoassay kit (Amersham). Protein was dissolved with 0.2N NaOH and measured using a bicinchoninic acid spectrophotometric method (BCA, Pierce Chemical Co).
Measurement of Inositol 1,4,5 -Trisphosphate-Releasable Calcium
The inositol 1,4,5-trisphosphate (IP 3 )-sensitive calcium pool was estimated using a modification of previously described methods. 23 Briefly, confluent VSMCs in 12-well culture dishes were loaded with 1 mCi/mL "Ca (Du Pont-NEN) for 30 minutes at 37°C. Loading and all subsequent steps were done in the presence of 5 mg/L ruthenium red (Eastman Kodak Co) to prevent calcium uptake by the mitochondria and 
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Fra 2. Bar graph shows effect of parathyroid hormone-( to block calcium-magnesium ATPase activity and calciuminduced calcium mobilization. 24 ' 25 Cells were washed twice with Hanks' buffered salt solution (Sigma) and incubated with either 100 nmol/L PTH(l-34), PTHrp(l-34), 10 mmol/L forskolin, or vehicle for 5 minutes at ambient temperature. After rapid removal of the treatment buffer, cells were immediately treated with 35 mmol/L digitonin (Sigma) in a HEPESbuffered salt solution with or without 10 mmol/L IP 3 (Calbiochem) for 5 minutes, and then 1-mL aliquots were collected for counting. The IP 3 -sensitive Ca 2+ was calculated by subtracting digitonin-released ^Ca from digitonin plus IP 3 -released 45 Ca. The results are expressed as the percentage of 43 Ca released that was attributable to IP 3 . Typically, IP 3 released from 8% to 17% (mean, 12.75%) of the total 43 Ca released from digitonin plus IPj-treated VSMCs.
To determine the dependence of PTH on adenylate cyclase in affecting IP 3 -releasable calcium, we first preincubated VSMCs with 100 mmol/L DDA for 20 minutes and then treated them as described above.
Statistical Methods
Results were analyzed using a statistics program (STATPAK, North West Analytical) on IBM-compatible personal computers. Student's / test and one-way ANOVA were used to determine significant differences between groups. A probability value less than .05 was considered significant. All results are expressed as mean±SEM.
Results
Basal [Ca 2+ ], in VSMCs incubated in 2 mmol/L CaCl 2 containing HPSS was 88.2±14.5 nmol/L and was unaffected by additions of PTH(l-34), PTHrp(l-34), or PTH . In vehicle-treated VSMCs, 100 nmol/L Ang II caused an immediate rise of [Ca 2+ ], that was attenuated by PTH(l-34) but not by the inactive PTH analogue PTH(3-34) (Fig 1) . PTH(l-34) decreased the peak response from 285.8±45.8 to 84.3±17.3 nmol/L (/><.001), whereas PTH(3-34) did not alter the peak response (Fig 2) . In a separate set of experiments, PTHrp(l-34) reduced the peak Ang H-induced [Ca 2+ ], response from 463.9±40.9 nmol/L (n=6) to 102.6±13.0 nmol/L (n=6,P<.001).
The attenuating effect of PTH(l-34) and PTHrp(l-34) was mimicked by IBMX, which raises cellular cAMP by inhibiting phosphodiesterase activity, and forskolin, which raises cellular cAMP by direct stimulation of adenylate cyclase ( ]i transients was reversed by treatment with H-8 but not by staurosporine (Table 1 ). H-8, which preferentially inhibits cAMP-and cGMP-dependent protein kinases, had no effect itself on the Ang II-induced [Ca 2+ ], response (288.3±33.9 nmol/L, n = l l , with vehicle; 312.1 ±84.0 nmol/L, n=6, with H-8), whereas it did abolish the attenuating effects of PTH(1-34) when added in combination with the PTH(l-34).
Pretreatment of VSMCs with the adenylate cyclase inhibitor DDA decreased the attenuating effects of both PTH(l-34) and PTHrp(l-34) (Figs 3 and 4) . DDA itself had no effect on the Ang II-induced [Ca Table 2) . Pretreatment of VSMCs with DDA attenuated these increases of cAMP concentration to near basal levels, as shown in Table 2 . The PTH(l-34) analogue, PTH(3-34), did not increase cAMP concentration significantly (10.70±0.31 pmol/mg protein, n=4), whereas forskolin increased 9.67±0.39 (15) 12.56±0.54* (15) 12.79±0.48* (6) 9.77*1.06 (4) 10.87±0.41t (16) 10.12±0.51t (7) PTH(1-34) Indicates rat parathyroid hormone-<1-34); PTHrp(1-34), parathyroid hormone-related proteln- (1-34) Ca was decreased from 12.5±1.5% to 1.3+0.2% (n=4). In a separate set of experiments, the ability of PTH(l-34) to attenuate IP 3 -releasable calcium was inhibited by DDA, the adenylate cyclase inhibitor. PTH(l-34) significantly decreased the amount of IP 3 -releasable calcium (Table 3) . DDA had no effect on 45 Ca release itself but prevented the effect of PTH(l-34).
Discussion
This study was designed to investigate the intracellular mechanism or mechanisms by which PTH(l-34) and PTHrp(l-34) may antagonize the effects of vasoconstrictor substances on vascular smooth muscle. Because elevation of [Ca 2+ ], is a primary signaling event that ultimately leads to contraction of vascular smooth muscle by many agonists, such as Ang II, our approach was to investigate the effects of PTH(l-34) and PTHrp(l-34) on Ang II-induced [Ca 2+ ], mobilization. Cultured VSMCs were chosen for this study because they are easily isolated and maintained in culture, respond to Ang II, and are suitable cells for measuring [Ca 2+ ],, cAMP, and IP 3 -releasable Ca 2+ . The present results strongly support the hypothesis that PTH(l-34) and PTHrp(l-34) attenuate mobilization of IP 3 -sensitive calcium stores in VSMCs through an adenylate cyclase-dependent mechanism. PTH(1-34) and PTHrp(l-34) share a common receptor and stimulate adenylate cyclase through a stimulatory G protein-modulated path in a variety of tissues. This action is mediated through the N-terminal portion of PTH and PTHrp, with specification residing at the first two amino acids of the peptides. 2627 The observation that PTH(l-34) and PTHrp(l-34) but not PTH(3-34) attenuated Ang II-induced calcium mobilization further supports the hypothesis that the important region for this action in VSMCs resides in the first two amino acids of these peptides. Further support for this mechanism is provided by the observation that IBMX and forskolin both mimicked this effect of PTH(l-34) and PTHrp(l-34) on VSMCs. Because IBMX, forskolin, PTH(l-34), and PTHrp(l-34) all increase cAMP, but through different mechanisms, it appears likely that cAMP may be the common factor through which these agents antagonize calcium mobilization. In this regard, PTH(l-34) has recently been shown to inhibit vasopressin-induced contraction of and Ca 45 uptake in VSMCs through a cAMP-dependent mechanism. 19 In addition to its effect in stimulating intracellular formation of cAMP, PTH(l-34) has been shown to stimulate formation of IP 3 , a product of phosphoinositide-specific phospholipase C (PLC) activation, and activate PKC in kidney and bone cells. 2830 However, PTH(l-34) does not increase IP 3 concentration in cultured VSMCs. 19 It has also been reported that PTH(1-34) causes an acute and transient increase of [Ca 2+ ]i in cultured VSMCs, 31 although this has not been confirmed by other investigators or in our studies. The possibility that PTH(l-34) activation of PKC may be responsible for its action in attenuating the effect of Ang II on [Ca 2+ ], seems unlikely, because staurosporine, a PKC inhibitor, did not modify the effects of PTH . However, these results must be interpreted cautiously because staurosporine could have additional effects on VSMCs other than PKC inhibition. In contrast, H-8, which inhibits both cAMP-and cGMPdependent protein kinases, prevented this PTH(l-34) effect, implying that a cyclic nucleotide-dependent kinase mediates this action of PTH(l-34).
The results using DDA to inhibit adenylate cyclase provide additional support for the involvement of a cAMP-dependent mechanism in the PTH(l-34)-and PTHrp(l-34)-produced attenuation of the action of Ang II. The DDA concentration that inhibited cAMP production in VSMCs in response to PTH(l-34) and PTHrp(l-34) also partially reversed the effects of PTH(l-34) and PTHrp(l-34) on Ang II-induced calcium mobilization. The incomplete reversal of the attenuating effects of PTH and PTHrp on the Ang II-induced [Ca 2+ ]i signal by DDA suggests that another mechanism not involving adenylate cyclase is partially responsible for this effect of these peptides in VSMCs. PTH(l-34) can inhibit L-type channels in cultured VSMCs, suggesting another mechanism by which this peptide decreases [Ca 2 *],. 12 However, it has been shown that cAMP can inhibit cation influx in intact arteries, 32 and it is thought that blockade of L-type channels by PTH(l-34) is also cAMP dependent. Therefore, it appears that an as yet unknown cAMP-independent mechanism accounts for some of the attenuating effects of PTH(l-34) and PTHrp(l-34) on the Ang II-induced [Ca 2+ ]i increase in the present studies.
Because PTH(l-34) attenuated Ang II-induced changes of [Ca 2+ ], under extracellular calcium-free conditions, PTH(l-34) must have inhibited the mobilization or release of Ca 2+ from intracellular stores, presumably the sarcoplasmic reticulum. It has been demonstrated that Ang II releases Ca 2+ from intracellular stores via PLC activation, with IP 3 inducing release of Ca 2+ from intracellular stores. 33 As PTH(l-34) and PTHrp(l-34) significantly reduced the amount of 45 Ca released by IP 3 in permeabilized VSMCs, one mechanism whereby PTH(l-34) and PTHrp(l-34) attenuate Ang II-induced increases of [Ca 2+ ]j appears to be through regulation of IP 3 -sensitive calcium stores. Furthermore, because this effect of PTH(l-34) and PTHrp(l-34) was completely abolished by treatment of VSMCs with DDA, this mechanism is apparently dependent on adenylate cyclase. cAMP may attenuate release of IP 3 -sensitive Ca stores through the phosphorylation of IP 3 receptors by a cAMP-dependent protein kinase, as demonstrated in platelet membranes, 34 or by other proposed mechanisms of cAMP action on intracellular calcium, such as increased sequestration of calcium into the sarcoplasmic reticulum by calcium ATPase. 35 Alternatively, cAMP could also stimulate a cGMP-dependent kinase, as has been shown to occur in cultured rat VSMCs, which could also decrease the Ang II-induced [Ca 2+ ], transient. 18 Whichever cyclic nucleotide-dependent protein kinase is involved, the present studies suggest a sequence of events whereby PTH(l-34) and PTHrp(l-34) stimulate adenylate cyclase in VSMCs, resulting in increased intracellular levels of cAMP that then inhibit the release of calcium from IP 3 -sensitive stores. Our results do not exclude the possibility that PTH(l-34)-or PTHrp(l-34)-generated cAMP may have other effects on the PLC-IP 3 axis, such as reduction of IP 3 production, as demonstrated by Wang et al.
Our studies provide evidence for an additional intracellular mechanism by which PTH(l-34) and PTHrp(l-34) may attenuate Ang II-induced vasoconstriction. Increases of vascular smooth muscle [Ca 2+ ]i are associated with contraction; in contrast, decreases are associated with relaxation. 36 Increase of [Ca 2+ ], is thought to be the primary signal by which many vasoconstrictive agents, such as Ang II, contract vascular segments. 37 Therefore, our results suggest that PTH(l-34) and PTHrp(l-34) relax contracted vessels in part by decreasing the amount of [Ca 2+ ], mobilized by vasoconstrictive agonists such as Ang II. This action of PTH(l-34) and PTHrp(l-34) is dependent on adenylate cyclase, and the resultant increase of cAMP inhibits the amount of calcium released by IP 3 from intracellular stores. If these same mechanisms are operative in vivo, they may represent a cellular mechanism, in addition to blockade of L-type channels and reduction of IP 3 production, by which acute administration of PTH(l-34) and PTHrp(l-34) dilates blood vessels and lowers blood pressure.
Finally, Ang II recently has been shown to induce expression of PTHrp mRNA in VSMCs, and it has been postulated that PTHrp may work as a local autocrine factor providing negative feedback to Ang II-induced VSMC growth and contraction. 38 Our studies suggest that putative negative feedback by PTHrp on Ang II-induced contraction occurs through an adenylate cyclase-dependent mechanism. Although the antagonistic action of PTHrp on VSMC growth appears to reside in the more distal portions of the peptide beyond the 34th amino acid, 38 we found that the ability of PTHrp (and PTH) to antagonize VSMC calcium mobilization was associated with the proximal 34-amino acid region of the peptide. PTH and PTHrp use the same receptor; a separate receptor or receptors for PTHrp have not been demonstrated. Because the presence of PTHrp has been demonstrated in vascular smooth muscle, it can be speculated that under physiological conditions, PTHrp but not PTH plays a role in the regulation of vascular smooth muscle tone and blood pressure in vivo. Although the physiological significance of the present in vitro observations is not yet established, it is suggested that under certain conditions PTHrp and/or PTH may be factors involved in the regulation of vascular reactivity and blood pressure.
